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Abstract
Background: Pressurized intraperitoneal aerosol che-
motherapy (PIPAC) has emerged as a novel method to
treat extensive, small volume peritoneal metastases. The
clinical use of chemotherapy containing aerosols repre-
sents a potential occupational health hazard. We report
the results of toxicological analysis during the first two
clinical PIPAC procedures performed at Ghent University
Hospital.
Methods: After extensive preparation and in vitro testing,
two patients were treated with PIPAC: the first using
doxorubicin (2.86mg in 51.43 mL) and cisplatin
(14.28mg in 164.3 mL), the second using oxaliplatin
(182.10mg in 186.42 mL). A standardized safety checklist
was developed and used. Aerosol delivery was combined
with electrostatic precipitation (ePIPAC). The following
samples were obtained at several time points and loca-
tions: environmental air, floor surface wipes, surgeon’s
gloves, surgeon’s hand wipes, circuit filters, and fluid
from the water seal collection chamber container placed
along the closed aerosol waste evacuating line. Platinum
concentration was measured in these samples using vol-
tammetry. Sample collection and analysis were per-
formed by an independent external laboratory.
Results: Platinum was not detected on the four floor
locations after both procedures (detection limit 0.02 ng/
cm2). Similarly, no platinum was detected in environmen-
tal air during both PIPACs at the surgeon’s or anesthe-
siologist’s position (detection limit 4.0–27 ng/m3). No
platinum contamination was detected on the hands,
outer pair of gloves, or inner pair of gloves of the surgeon
(detection limit 70 and 50 ng respectively). Platinum was
not detected on the filters and in the air-seal container
liquid.
Conclusions: With adequate preparation and precau-
tions, a clinical PIPAC program can be established with-
out measurable chemotherapy exposure to the operating
room environment or healthcare workers.
Keywords: carcinomatosis, occupational, PIPAC
Introduction
Peritoneal metastasis is a defining feature of stage III
ovarian cancer and occurs in approximately 13% of gastric
cancers, 9% of pancreas cancers, and 8% of colorectal
cancers [1–4]. In selected patients, cytoreductive surgery
combined with hyperthermic intraperitoneal chemoperfu-
sion (HIPEC) results in a significant survival advantage
compared to palliative treatment alone [5, 6]. The morbid-
ity of the combined procedure is, however, considerable,
and a substantial proportion of patients have locally irre-
sectable disease [7].
In 2012, Marc Reymond and coworkers proposed, in an
animal model, a novel approach to intraperitoneal drug
delivery, during which chemotherapy is administered as
an aerosol during CO2 pneumoperitoneum [8]. The aerosol
is generated by a high pressure line connected to a nozzle,
hence the term pressurized intraperitoneal aerosol che-
motherapy or PIPAC. Advantages of this approach include
minimal morbidity, efficient drug distribution, and tissue
penetration, and the possibility to repeat the procedure
which allows for visual and histological assessment of
treatment response. In patients with widespread, small
volume but unresectable peritoneal metastasis, prelimin-
ary clinical experience has demonstrated the safety and
antitumor efficacy of PIPAC [9–11]. Recently, the same
group proposed to combine nebulization of chemotherapy
with electrostatic precipitation using the Ultravision™ sys-
tem. This device, originally developed to clear smoke from
the laparoscopic operating field using an electrostatic
force, uses a stainless steel microfilament brush
(Ionwand™) which is inserted into the abdominal cavity.
A high DC voltage (7.5–9.5 kV, ≤ 10 µA) is applied to the
wand resulting in a corona discharge and a stream of
negatively charged ions, which attach to suspended
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particles. These now negatively charged smoke particles
are attracted to the positively charged tissue surfaces of
the abdominal cavity, which is conferred a weak positive
charge by the patient return electrode. In theory, the com-
bination of electrostatic precipitation with PIPAC, termed
ePIPAC, could result in better tissue penetration of the
aerosol. In a recent porcine model, the addition of electro-
static precipitation to PIPAC resulted in higher tissue con-
centrations of a tracer substance [12]. The first clinical
application in three patients with peritoneal metastases
was recently reported, and showed ePIPAC to be techni-
cally feasible and well tolerated [13].
A possible drawback of (e)PIPAC is the challenge to
safely deliver a chemotherapy aerosol intraperitoneally
during laparoscopy, while preventing exposure of the
involved healthcare workers. In 2013, the group of
Reymond in Bochum performed analytical measurements
of air samples during two PIPAC procedures [14]. Two
patients were treated with PIPAC using cisplatin (7.5mg/
m2) and doxorubicin (1.5mg/m2); analysis of air samples
taken at the place of the surgeon as well as that of the
anesthesiologist was unable to detect cisplatin air con-
tamination (detection limit < 0.000009mg/m3). Graversen
and coworkers from the Odense University Hospital in
Denmark recently reported the results of air sample ana-
lysis and biological monitoring in two surgeons during
and after PIPAC in two patients: one treated with cispla-
tin and doxorubicin, and the second treated with oxali-
platin [15]. No traces of platinum were found in the air
samples (detection limit 0.0001mg), and blood samples
of the surgeons showed no traces of platinum.
Here, we report an additional, comprehensive toxico-
logical analysis including air samples, surface wipe sam-
ples, and analysis of surgeon’s gloves and hands after
clinical PIPAC procedures using cisplatin/doxorubicin
and oxaliplatin.
Patients and methods
Description of the standard PIPAC procedure used
at Ghent university hospital (Figure 1)
A 12mm balloon trocar (Applied Medical, Amersfoort, The
Netherlands) is inserted and a 12mmHg pneumoperitoneum is estab-
lished. A 5mm balloon trocar (Applied Medical, Amersfoort, The
Netherlands) is then placed under direct vision. Any ascites is aspi-
rated, sampled for cytology and/or bacteriology, and its volume is
noted. If needed, limited careful adhesiolysis is performed to allow a
complete exploration of the peritoneal cavity and to calculate the
extent of peritoneal carcinomatosis using the peritoneal cancer
index. Particularly, intestinal dilatation from malignant adhesions,
a precursor of obstruction to occur erelong, is assessed. Next, to
estimate the therapeutic effects of subsequent PIPACS, biopsies of
peritoneal nodules marked by clips are taken in both upper and
lower abdominal quadrants and digital photographs are obtained
throughout the peritoneal cavity.
Next, the electrostatic PIPAC or ePIPAC injection system is
installed (Figure 1). A stainless steel brush electrode (Ionwand™)
is inserted into the peritoneal cavity and connected with a dedicated
catheter that is placed in the generator unit of the Ultravision System
(Alesi Surgical, Cardiff, UK). The Ultravision System is turned on
after complete nebulization of the chemotherapy. Prevention of
exposure of the surgical team to chemotherapy must be guaranteed
by preventive measures taken during installation of the ePIPAC
injection system. Because maintenance of a leak-free pneumoperito-
neum of 12mm Hg is essential, every potential cause of spread of
aerosol from the pneumoperitoneum through the trocars must be
evaluated. Therefore, airtight balloon trocars are used; the port of
the balloons is closed with a cap; the luer lock of the 5mm trocar is
closed; and the CO2 inflator tube, which is connected with the 12mm
balloon trocar, has a KV-5 filter (Olympus, Hamburg, Germany) at its
Figure 1: Schematic overview of the
ePIPAC setup used at Ghent University
Hospital, and of the different samples
that were obtained for analysis (1–10).
CAWS, closed aerosol waste system.
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origin to prevent chemotherapy to enter the insufflator. A high
pressure line sealed to the nebulizer (CapnoPen™, Capnomed
GmbH, Villingendorf, Germany) and surrounded by a plastic camera
cover is used. The nebulizer is then inserted in the 12mm balloon
trocar and secured with the tip just inside the peritoneal cavity. The
tip is permanently visualized with a 5mm 30° camera (EndoEye™,
Olympus, Hamburg, Germany) that is placed in the 5mm balloon
trocar and secured with a laparoscopic scope holder (Integra,
Zaventem, Belgium, and Cook Medical, Limerick, Ireland). After
completion of the ePIPAC procedure, the abdomen is desufflated
using a line attached to the 5mm trocar and equipped with a smoke
evacuation filter (MTP Gmbh, Neuhausen Ob Eck, Germany). After
CO2 has passed through this filter, it enters a water seal drainage
system (Atrium, Mijdrecht, The Netherlands) that is attached to a
wall-mounted suction unit equipped with an infant-pediatric elec-
trostatic filter HME (Medtronic, Brussels, Belgium). This closed
waste evacuation assembly is installed before the start of the proce-
dure. After completing the ePIPAC installation, protective sheets are
laid out under the injector and next to the patient; team members
wear safety glasses and two pairs of gloves (outer pair: Gammex™;
inner pair: Gammex Latex Chemo™, both Ansell Healthcare,
Brussels, Belgium) and chemotherapy waste containers are provided
in the operating room. Then, patient’s name and chemotherapy dose
on the label of the chemotherapy infusion bag are verified and
chemotherapy is completely aspirated through an infusion line
into the syringe(s) of the Accutron™ CT-D injector (Euro Medical,
Ham, Belgium). Afterward, the end of the syringe is firmly connected
to the high pressure line and this connection is surrounded with the
plastic camera cover. Then, standard injector settings for ePIPAC are
applied (i. e., flow rate of 30 mL/min and maximal pressure of 20
Bar). Before the team leaves the operating room, patients are curar-
ized for 40 minutes; laminar air flow is activated, and an ePIPAC
door warning sign ensures that everyone is kept out the operating
room during ePIPAC. The locally used ePIPAC safety checklist is
provided as Appendix.
Outside the operating room, the injector is activated through a
remote control system that allows real-time assessment and control
of the established pressure in the nebulizer, the flow rate of the
injected chemotherapy and the administration time. A DVI cable
that passes through the operating room wall provides real-time
laparoscopy imaging and monitoring of the anesthesiology proce-
dure. After complete administration of the chemotherapy (i. e., 5–6
minutes, depending on the dose), the surgeon enters the operating
room and activates the Ultravision™ System. A pneumoperito-
neum of 12mmHg is maintained for 30 minutes and promotes
tumor penetration of chemotherapy. After ePIPAC, the surgeon
desufflates the pneumoperitoneum and laparoscopic incisions are
closed.
Description of the clinical procedures performed for the
biohazard analysis
On September 23rd 2015, the first two ePIPACs were performed at
Ghent University Hospital, Belgium. The first procedure was done in
a male 52 years old patient with a diffuse-type signet-ring cell gastric
adenocarcinoma. After neoadjuvant treatment with docetaxel, cis-
platin and fluorouracil, a total gastrectomy (ypT4aN2M0) was per-
formed followed by radiotherapy (50.4 Gy) and fluorouracil.
Metachronous peritoneal carcinomatosis was diagnosed after 10
months and treated with fluorouracil plus leucovorin and irinotecan
in combination with ePIPAC using doxorubicin (2.86mg in 51.43 mL)
and cisplatin (14.28mg in 164.3 mL). The second ePIPAC was per-
formed in a 80 years old male patient with a history of a well-
differentiated sigmoid adenocarcinoma (pT4bN2aM0). Adjuvant
capecitabine was administered after sigmoid resection. Seventeen
months after diagnosis, metachronous peritoneal carcinomatosis
was observed and treated with cytoreductive surgery and intraper-
itoneal chemotherapy. Six months later, ePIPAC with oxaliplatin
(182.10mg in 186.42 mL) was initiated because of recurrent perito-
neal disease.
Sample collection
Wipe samples were taken from potentially contaminated floor sur-
faces in the operating room after the PIPACs. For wipe sampling,
Cyto Wipe Kits were used (Exposure Control Sweden AB, Bohus-
Björkö, Sweden). The wipe samples were taken with 2 tissues and
17 mL of 0.05M HCl. The liquid was dripped on the defined surface
and spread over the whole surface with one tissue. The second
tissue was used to remove the remaining liquid from the surface.
Both tissues were collected. A blank sample (2 tissues and 17 mL
0.05M HCl) was also analyzed. The air samples were collected
according to standard procedures. Institute of Occupational
Medicine (IOM)-samplers connected to VSS-5 Buck pumps (A.P.
Buck Inc., Orlando, USA) were used. Total particulate matter was
collected on polytetrafluoroethylene (PTFE) filters (25mm diameter
and 1.0 µm pore size, Whatman, GE Healthcare UK Limited, Little
Chalfont, United Kingdom). The air flow was 2.0 L/min. A blank
sample (filter) was also analyzed. Both pairs of surgeon gloves
were collected and analyzed for contamination. The hands of the
surgeon were checked for contamination to establish if the double
pair of gloves offered effective protection. The hands were wiped
with 3 moist tissues (verfrissingsdoekjes, Kruitvat, Renswoude, The
Netherlands). Blank samples (gloves and 3 moist tissues) were also
analyzed. To ascertain that the results of the monitoring study were
not influenced by previous working activities, a cleaning was
performed before the first PIPAC, and wipe samples were collected
before and after cleaning. Stationary air samples were collected
during the night before the PIPAC to measure background levels of
platinum in the operation room.
Sample storage, preparation and analysis
After sampling and during transport to the lab, all samples were
stored at room temperature followed by storage at -20 °C until sam-
ple preparation and analysis.
A known volume of 0.5M HCl was added to the wipe samples,
gloves, tissues of the hands, and the filters followed by extraction.
Next, 0.5mL extract or water seal liquid (no extraction needed) was
destructed with hydrogen peroxide and hydrogen acid using UV
light. During this process, platinum containing cytostatic drugs
such as cisplatin and oxaliplatin but also other platinum containing
compounds are converted into platinum (PT) ions [12]. Hence, it is
very important that no contamination is observed in the environ-
ment from previous surgical activities before the PIPAC as this could
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negatively influence the results. Platinum was finally analyzed
with voltammetry on a Computrace (Metrohm Ltd, Herisau,
Switzerland) [16]. The results were corrected for potential back-
ground values of platinum (compounds) being present in the envir-
onment but who were not from platinum containing drugs. The
detection limit for platinum was set at 0.5 ng/mL HCl extract.
Results
Platinum was not detected on the four floor positions
after both PIPACs (Table 1). This was also the case for
the background testing before cleaning and before PIPAC
1 indicating no contamination before the start of PIPAC 1.
The limit of quantification was 0.02 ng/cm2. Platinum
was not detected in environmental air during both
PIPACs (Table 2). This was also the case for the back-
ground testing after cleaning the day before indicating no
platinum in environmental air before the start of PIPAC 1.
The limit of quantification depending on the air volume
collected was between 4.0 and 27 ng/m3.
Platinum was not detected on the hands, and the
outer and inner pair of gloves of the surgeon (Table 3).
The limit of quantification was 70 and 50 ng, respec-
tively. Platinum was not detected on the filters and in
the liquid of the water locks (Table 4).
Discussion
The perioperative use of cytotoxic agents demands close
attention to the occupational health risks of the involved
staff. Based on in vitro studies, animal experimentation,
and epidemiological data, the International Agency of
Research on Cancer (IARC) classifies some cytotoxic agents
in Group 1 (carcinogenic to humans; includes chlorambu-
cil and cyclophosphamide), Group 2A (probably carcino-
genic to humans; includes cisplatin and doxorubicin), and
Group 2B (possibly carcinogenic to humans; includes mito-
mycin-C) [17]. There are no published epidemiological or
experimental data on the carcinogenicity of oxaliplatin,
and it is not listed by the IARC. Nevertheless, given the
similarity to cisplatin in structure and DNA interaction, a
similar degree of carcinogenicity is probable. The health
risks of occupational exposure to cytotoxic drugs have
been documented. A recent meta-analysis showed a 67%
higher frequency of micronuclei in peripheral lymphocytes
(a marker of genome toxicity) in exposed health care work-
ers compared to controls [18].
The results from studies investigating the occupa-
tional hazards for personnel involved in HIPEC proce-
dures have been recently reviewed [19]. In summary,
none of the included studies could detect platinum or
mitomycin C in urine or plasma of health care workers,
or in air samples. Villa and coworkers identified the
operating table, operating room floor, and surgeon’s
overshoes as the most important sources of contamina-
tion after open HIPEC with oxaliplatin [20].
Protection of the health care personnel and working
environment becomes even more critical when, during
PIPAC, chemotherapy is administered as an aerosol.
Monitoring of surface contamination by wipe sampling,
measuring glove and skin contamination is rather easy
to perform and is a standard procedure in many
hospitals where cytostatic drugs are prepared and admi-
nistered. Monitoring is a tool to evaluate routines,
procedures and cleaning to prevent environmental con-
tamination and potential exposure to hazardous drugs
known to cause adverse health effects [21].
The first safety analysis of the procedure was
reported by Solass and colleagues in 2013 [14]. Two
patients were treated with PIPAC using cisplatin
(7.5mg/m2) and doxorubicin (1.5mg/m2); analysis of air
samples taken at the place of the surgeon as well as that
of the anesthesiologist was unable to detect cisplatin air
Table 1: Analysis of surfaces for presence of platinum (PT).
Description of the surfacea PT,
ng/mL HClb
PT,
ng/cm
PT,
ng/mL HClb
PT,
ng/cm
PT,
ng/mL HClb
PT,
ng/cm
PT,
ng/mL HClb
PT,
ng/cm
Background before
cleaning
Before PIPAC After PIPAC  before
cleaning
After PIPAC  before
cleaning
Floor surgeon ND <. ND <. ND <. ND <.
Floor drug administration ND <. ND <. ND <. ND <.
Floor drug suction equipment ND <. ND <. ND <. ND <.
Floor anesthesiologist ND <. ND <. ND <. ND <.
aSurface area 4900 cm2. bTotal extraction volume 160 mL. ND, not detected ( <0.5 ng/mL HCl).
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contamination (detection limit < 9 ng/m3). Recently,
Graversen and coworkers reported the results of air sam-
ple analysis and biological monitoring in two surgeons
during and after PIPAC in two patients [15]. Importantly,
the blood analyses were undertaken after 50 PIPAC pro-
cedures were performed. No traces of platinum were
found in the air samples or in the surgeon’s blood. In
the present study, we have analyzed contamination of
floor surfaces, surgeon’s gloves and hand surface, and
waste circuit components in addition to air samples. We
did not analyze blood samples, since cisplatin is rapidly
metabolized and reliable detection of systemic Pt expo-
sure would require serial urinary sample analyses. Our
results confirm that, after PIPAC with cisplatin or oxali-
platin, no detectable platinum is present in large volume
air samples taken close to the surgeon and anesthesiolo-
gist, with a detection limit of 4.0–27 ng/m3. Moreover,
and reassuringly, no platinum was detected in either the
filters or in the water contained in the water seal reser-
voir. This suggests that the electrostatic precipitation at
the end of the aerosol delivery ensures complete absorp-
tion of the drug by the peritoneal contents.
Table 3: Analysis of gloves and hands of the surgeon for the pre-
sence of platinum (PT).
PIPAC Gloves and hands Total
extraction
volume
HCl, mL
PT, ng/mL
HCl
PT,
ng
 Outer pair of gloves
surgeon (white)
 ND <
 Inner pair of gloves
surgeon (blue)
 ND <
 Hands surgeon ( tissues)  ND <
 Outer pair of gloves
surgeon (white)
 ND <
 Inner pair of gloves
surgeon (blue)
 ND <
 Hands surgeon ( tissues)  ND <
Blank Outer pair of gloves
(white)
 ND <
Blank Inner pair of gloves (blue)  ND <
Blank  Tissues  ND <
ND, not detected ( <0.5 ng/mL HCl).
Table 4: Analysis of waste line components for the presence of
platinum (PT).
PIPAC Description Total
extraction
volume HCl, mL
PT,
ng/mL
HCl
PT,
ng
 Smoke evacuation filtera  ND <
 Infant-pediatric
electrostatic filter HMEb
 ND <
 Liquid from water seal
drainage
 ND <
 Smoke evacuation filtera  ND <
 Infant-pediatric
electrostatic filter HMEb
 ND <
 Liquid from water seal
drainage
 ND <
ND, not detected ( <0.5 ng/mL HCl). aMTP GmbH, Neuhausen Ob Eck,
Germany. bMedtronic, Brussels, Belgium.
Table 2: Analysis of environmental air samples for the presence of
platinum (PT) .
Locationa Sampling
time, min
Air
collected,
L
Total
extraction
volume
HCl, mL
PT,
ng/mL
HCl
PT,
ng/m
Left of surgeon
(stationary)
   ND < .
Drug
administration
(stationary)
   ND < .
Drug suction
equipment
(stationary)
   ND < .
Anesthesiologist
(personal)
   ND < 
Surgeon
(personal)
   ND < 
Left of surgeon
(stationary)
   ND < .
Drug
administration
(stationary)b
   ND < 
Drug suction
equipment
(stationary)
   ND < .
Anesthesiologist
(personal)
   ND < 
Surgeon
(personal)c
   ND < 
Left of surgeon
(stationary)
   ND < 
Drug
administration
(stationary)
   ND < 
Drug suction
equipment
(stationary)
   ND < 
Blank – –  ND
ND, not detected ( <0.5 ng/mL HCl). aStationary sampling about 150 cm
above the floor; samples left of surgeon 180 cm above the floor during
PIPAC. bSampling intermittent (technical failure). cSampler partly cov-
ered by gown; sampling started at administration of the drug.
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We were unable to identify platinum contamination of
either the inner or the outer pair of surgeon’s gloves. In
contrast, during HIPEC with open abdomen perfusion and
the surgeon’s hand stirring the abdominal contents, glove
contamination is considerable. Regardless of the procedure,
prevention of cutaneous exposure by wearing appropriate
gloves is essential. In Europe, there are no specific require-
ments or test methodologies for medical gloves used for
handling cytotoxic agents. In contrast, in the US medical
gloves used for this purpose must fulfill the ASTM
International (American Society of Testing and Materials)
standard D 6978-05 requirements. Nitrile or natural rubber
latex are the preferred basic glovematerials. Importantly, all
glove material displays a general trend towards greater per-
meation over time (fivefold increase between 15 and 60min).
[22] Therefore, a glove change is recommended every 15–20
minutes, or more frequent with increasing temperature or
continuous hand movement.
In conclusion, using the proposed technical setup
and precautions, we were unable to detect any surface,
air, or material contamination with platinum during or
after two clinical PIPAC procedures. These results con-
firm that, with adequate preparation, a clinical PIPAC
program can be established without measurable che-
motherapy exposure to health care workers. It is recom-
mended that toxicological analyses are performed before
starting a clinical PIPAC program in order to ensure
adequacy of the protective measures that are put in place.
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Appendix
Before ePIPAC
Installation of the ePIPAC injection system
. Patient name: … … … … … … … … … … … … … … … … … … …
… … … … … … … … … … … … … … …
. Date: … . … . … … … … … … … … … … … … … … … … … … …
… … … … … … … … … … … … … … .
. Chemotherapeutic agent(s) ordered? O
. Laparoscopy pictures taken? O
. PCI and ascites volume noted? O
. Biopsies taken at four abdominal quadrants and marked
with clips?
O
. Electrode placed and connected to Ultravision System? O
. Ultravision System turned off? O
. Patient return electrode placed and connected with
electrosurgical generator?
O
. Pneumoperitoneum airtight at mmHg? O
. Cap applied to balloon port of both trocars? O
. Port of mm trocar closed? O
. Filter system connected to mm trocar? Clamp closed? O
. Filter system connected to water seal drainage system? O
. Water seal drainage system connected to a wall-mounted
suction unit with filter?
O
. Two cm water seal established? O
. Water seal drainage system in function? O
. CO tube with filter connected to mm trocar? Port open? O
. Micropump fixed in mm trocar and end just in the
peritoneal cavity?
O
. Is the micropump connected to a high pressure line? O
. High pressure line and micropump flushed? O
. Plastic camera cover fixed to the micropump with adhesive
strip?
O
. Camera placed in the mm trocar and fixed with
laparoscopic camera holder?
O
. Clothing, gloves, instruments and stitches for wound
closure present?
O
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Aspiration of chemotherapy
ePIPAC
Completing the procedure
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